Wells Fargo
TLIS

Wells Fargo’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Wells Fargo’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13
Closed -$114 – 7634
2024
Q1 		$114 Hold
13
– – ﹤0.01% 6621
2023
Q4 		$97 Buy
13
+1
+8% +$7 ﹤0.01% 6783
2023
Q3 		$69 Hold
12
– – ﹤0.01% 6849
2023
Q2 		$84 Buy
12
+1
+9% +$7 ﹤0.01% 6915
2023
Q1 		$82 Hold
11
– – ﹤0.01% 6981
2022
Q4 		$73 Hold
11
– – ﹤0.01% 6885
2022
Q3 		$0 Buy
11
+4
+57% +$51 ﹤0.01% 7591
2022
Q2 		$0 Sell
7
-198
-97% -$3.13K ﹤0.01% 7702
2022
Q1 		$4K Sell
205
-330
-62% -$11.4K ﹤0.01% 6546
2021
Q4 		$32K Buy
+535
New +$40K ﹤0.01% 6169
2021
Q3 		– Sell
-1,304
Closed -$216K – 7680
2021
Q2 		$216K Buy
1,304
+1,028
+372% +$175K ﹤0.01% 4995
2021
Q1 		$53K Buy
+276
New +$68.8K ﹤0.01% 5794

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Wells Fargo's TLIS Position: Q2 2024 in Review

Wells Fargo sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q2 2024, closing a stake of 13 shares — an estimated $114 sold.

Wells Fargo first reported a position in TLIS in Q1 2021 and held it in 12 quarters. The position peaked at $216K in Q2 2021. 18 funds tracked by Wall St. Rank hold TLIS as of Q2 2024.

  • Wells Fargo reported no remaining Talis Biomedical Corporation Common Stock position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 13 Talis Biomedical Corporation Common Stock shares in Q2 2024, an estimated $114.
  • Wells Fargo first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 12 quarters.
  • Wells Fargo's Talis Biomedical Corporation Common Stock position peaked at $216K in Q2 2021.
  • 18 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.